BLUEBIRDBIO
Bristol Myers Squibb - bluebird bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual
Bluebird Bio Resumes Marketing Of Gene Therapy Zynteglo For β-Thalassaemia In Europe – TIF
1 News - BLUEBIRD Consulting informs
Bluebird has pawned off the second of two PRVs for $95M
Bluebird Bio Says Cash Crunch Raises 'Going Concern' Risk - Bloomberg
blue-ex991_25.htm
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock - intelligence360
SEC Filing - bluebird bio, Inc.
blue-ex991_25.htm
bluebird bio submits BLA for single-dose gene therapy to treat beta-thalassemia
Gene Therapy LentiGlobin Granted Priority Medicines Designation for Sickle Cell Disease in the EU – TIF
SEC Filing - bluebird bio, Inc.
bluebird bio Completes Oncology Spin-Off Business, Establishes New Nest | BioSpace
Bluebird bio receives EC Approval for SKYSONA™ for Early Cerebral Adrenoleukodystrophy (CALD) - Newsletter
bluebird bio on LinkedIn: bluebird bio has been setting the standard in gene therapy for nearly a…
bluebird bio's Zynteglo (betibeglogene autotemcel) Receives the US FDA's Approval for the Treatment of Beta-Thalassemia
bluebird bio plans 'new nest' around hybrid work model
Bluebird Bio Secures Deal with Large Commercial Payer for Lyfgenia Amid Price Concerns | BioSpace
Bristol Myers Squibb - Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for Adults with Relapsed and Refractory Multiple Myeloma
bluebird bio's Pricing Strength Expands Their Potential (NASDAQ:BLUE) | Seeking Alpha
SEC Filing - bluebird bio, Inc.
FDA Grants Bluebird Bio Priority Review of BLA for SCD Treatment
SEC Filing - bluebird bio, Inc.
